
KT earnings miss, Revenue Inline in Q2
Investing.com - KT reported on Tuesday second quarter {{erl-39284||earnings that missed analysts' forecasts and revenue that was inline with expectations. KT announced earnings per share...
Investing.com - KT reported on Tuesday second quarter {{erl-39284||earnings that missed analysts' forecasts and revenue that was inline with expectations. KT announced earnings per share...
Investing.com - POSCO reported on Tuesday second quarter {{erl-21260||earnings that beat analysts' forecasts and revenue that topped expectations. POSCO announced earnings per share of...
By Scott Kanowsky Investing.com -- Sanofi SA (EPA:SASY) shares slid on Wednesday after the French drugmaker announced that it will halt trials of a new treatment for patients battling...
Investing.com - Analog Devices (NASDAQ:ADI) reported on Wednesday third quarter {{erl-7869||earnings that beat analysts' forecasts and revenue that topped expectations. Analog Devices...
Investing.com - TJX (NYSE:TJX) reported on Wednesday second quarter {{erl-8227||earnings that beat analysts' forecasts and revenue that fell short of expectations. TJX announced earnings...
The Indian finance minister suggested against using cryptocurrency.The law enforcement organization blocked the assets of two crypto exchanges.At a BJP Economic Cell event on Saturday,...
(Bloomberg) -- Europe’s benchmark power price rose to a record for a fifth consecutive trading session as there are no signs of the natural gas rally slowing down. German year-ahead power...
Pre-Open Stock Movers: Athenex (NASDAQ:ATNX) 61% HIGHER; reports from the Economic Times that Intas and Dr. Reddys Labs (RDY) are in talks to acquire the company for $200-$250...
Athenex Inc (NASDAQ: ATNX) shares climbed during the after-hours session as India's Intas Pharmaceuticals and Dr Reddy's Laboratories Ltd (NYSE: RDY) are reportedly in talks to acquire...
After-Hours Stock Movers: Athenex (NASDAQ:ATNX) 61% HIGHER; reports from the Economic Times that Intas and Dr. Reddys Labs (RDY) are in talks to acquire the company for $200-$250...
Athenex, which is into the development of cell therapies to treat cancers, had hired investment advisory firm Cowen Inc to run a formal process to find a buyer. "A formal process has started...
Athenex , Inc. (NASDAQ:ATNX) reported Q2 EPS of ($0.28), $0.13 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $31.51 million versus the consensus estimate...
BUFFALO, N.Y., July 25, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel...
BUFFALO, N.Y., July 21, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel...
Investing.com – U.S. equities were higher at the close on Monday, as gains in the Technology, Industrials and Oil & Gas sectors propelled shares higher. At the close in NYSE, the Dow Jones...
Investing.com – U.S. equities were mixed at the close on Tuesday, as gains in the Healthcare, Financials and Technology sectors propelled shares higher while losses in the Telecoms, Oil &...
Investing.com – U.S. equities were lower at the close on Monday, as losses in the Basic Materials, Industrials and Technology sectors propelled shares lower. At the close in NYSE, the Dow...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.